All Articles

A novel drug aims to reverse myelin damage in MS, a feat no current therapy can achieve. But with a recent FDA hold, is Quantum BioPharma's vision a breakthrough or a mirage?

With a new AI research lab and a $52M Series A, Niural is tackling the hardest problem in AI: building agents for domains where the margin for error is zero.

A new US policy designates cartels as terrorists, turning Latin American banks into a compliance minefield. The stakes are existential, and the financial network is the front line.

Hamilton just opened a $390M transit facility. It's not just a garage; it's the critical nerve center for the city's ambitious future of growth and mobility.

With 4K laser projectors at 50% off, Dangbei is betting big that consumers will ditch the TV for a massive, cinematic experience that disappears on command.

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.

For 10 years, Charles Schwab has been one of America's most community-minded firms. We dissect how its integrated model is more than charity—it's a strategy.

Former AF Group CEO Elizabeth Haar joins Prescient National's board, signaling a major strategic push to reshape its national footprint and innovate.

NewtekOne just automated a tedious part of getting a business loan. But the real story is its plan to sell this tech to other banks, changing its own game.

A new partnership puts high-purity recycled plastic in food containers, a breakthrough that helps brands meet tough new laws and growing consumer demand.

Quoin Pharma's new drug name is a key step, but the path to the first-ever treatment for a rare skin disease reveals the complex interplay of innovation and finance.

Europastry's acquisition of Highland Baking isn't just a deal; it's a strategic fusion of global scale and artisan quality set to reshape the US market.

Freedom Bank's appointment of Purnachandra Dokku signals a bold new strategy, embedding deep cybersecurity and real estate expertise into its governance.

By launching a Quality of Earnings practice under expert Ryan Irby, GA Group completes its advisory suite, a strategic move to master a complex M&A market.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

A new study from Keypoint Intelligence aims to cut through the noise as cloud, security, and Microsoft reshape the multi-billion dollar print management industry.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

A Bitcoin miner is betting its future on AI, repurposing its power grid to chase the tech industry's insatiable demand for energy. Is this the new blueprint?